405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments

J.E. Ang; J.A. Clarkson-Jones; H. Swaisland; A.T. Brunetto; R. Lal; A.P. Farnsworth; L.R. Molife; S.B. Kaye; J. Carmichael; J.S. de Bono

首页> 外文期刊>European Journal of Cancer Supplements >405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments

【24h】

405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments

机译：405一项质量平衡研究，以研究[14C]-奥拉帕尼（AZD2281）在标准治疗难以治疗的晚期实体瘤患者中的代谢，排泄和药代动力学

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第7期|共2页
作者
J.E. Ang; J.A. Clarkson-Jones; H. Swaisland; A.T. Brunetto; R. Lal; A.P. Farnsworth; L.R. Molife; S.B. Kaye; J. Carmichael; J.S. de Bono;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [~14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors [J] . Xiaofei Zhou, Seepraj Pusalkar, Swapan K. Chowdhury, Investigational new drugs. . 2019,第4期

机译：质量平衡，排泄途径，研究口服的药代动力学 - alisertib（MLN8237），一种高级实体瘤患者的激酶抑制剂
2. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours [J] . O A Khan, M Gore, P Lorigan, British Journal of Cancer . 2011,第5期

机译：奥拉帕尼（AZD2281，KU0059436）和达卡巴嗪在晚期实体瘤患者中的安全性和耐受性的I期研究
3. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. [J] . Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, Cancer science. . 2012,第3期

机译：在患有晚期实体瘤的日本患者中进行olaparib（AZD2281）的I期，剂量发现和药代动力学研究。
4. Investigations of the biodistribution and phototherapeutic utility of two palladium(II)-containing macrocyclic drugs in a tumour-bearing mouse model: A study of the pharmacokinetics and tissue distribution of the potential photodynamic drug palladium-bacteriopheophorbide as well as the in vivo treatment efficacy and tissue distribution of the potential photothermal drug palladium(II) octabutoxynaphthalocyanine. [D] . DeGroot, Jennifer Leanne. 2002

机译：两种含钯（II）的大环药物在荷瘤小鼠模型中的生物分布和光疗实用性的研究：潜在的光动力药物钯-细菌脱镁叶绿酸的药代动力学和组织分布以及体内治疗效果和研究光热药物钯（II）八丁氧基萘酞菁的组织分布。
5. A Phase I dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors [O] . Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, 2012

机译：日本晚期实体瘤患者奥拉帕里布（AZD2281）的I阶段I剂量查找和药代动力学研究
6. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. [O] . Khan, OA, Gore, M, Lorigan, P, 2011

机译：I期研究奥拉帕尼（AZD2281，KU0059436）和达卡巴嗪在晚期实体瘤患者中的安全性和耐受性。

405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments

著录项

相似文献

相关主题

期刊订阅